Bullous fixed-drug eruption with intraoral lesions due to mefenamic acid: A case report

Authors

  • Anis Puspita Utami Meilia Hospital Cibubur, Indonesia.
  • Levina Ameline Moelyono Faculty of Medicine, Diponegoro University, Semarang, Indonesia.
  • Ratrisha Anadya Faculty of Medicine, Padjajaran University, Semarang, Indonesia.
  • Rahmadia Kusumamardhika PMI Hospital, Bogor, Indonesia.
  • Erdina Dermatology Department, PMI Hospital, Bogor, Indonesia.

DOI:

https://doi.org/10.66344/jpad.33.2.2023.2159

Abstract

Introduction: Bullous Fixed drug eruption (BFDE) is a form of skin and mucocutaneous allergic reaction formed as purplish plaque or bullae with purple base in the same previous place due to certain medication. One of the drug is known to trigger FDE is non-steroidal antiinflammation drugs (NSAIDs) including mefenamic acid. Clinically, FDE is often mimic Steven-Johnson syndrome with milder clinical symptoms. Case Illustration: A 24-year-old male came with complaint of multiple red spots with blisters and itch on his trunk, back, and leg. He also complained about his white painful scaled lip and lesion in his mouth since 1 day ago after he took mefenamic acid. The patient had the same complaint 1 year ago. Dermatological status showed multiple purpuric annular and oval well-demarcated lesions and tension bullae on his back and right leg. Less-demarcated erythema lesion were seen on his trunk. On his lips there were oedema with white desquamation and white lesions on his tongue along with multiple intraoral erosion. Blood examination showed good results. The patient was diagnosed with bullous fixed drug eruption and was treated with methylprednisolone injection 2x62,5mg with gradual tapering-off, ranitidine injection 2x50mg, and ringer lactate fluid 500cc per 12 hour. In 3 days the patient showed clinical improvement. Conclusion: Clinical manifestations of bullous fixed drug eruption are often mimic other dermatosis and can be differentiate with history of taking triggering medication and the place of the lesions. Education according drug-induced allergy is essential to prevent lesions recurrency.

References

Jung JW, Cho SH, Kim KH, Min KU, Kang HR. Clinical Features of Fixed Drug Eruption at a Tertiary Hospital in Korea. Allergy Asthma Immunol Res. 2014;6(5):415.

Ngwasiri CA, Abanda MH, Aminde LN. Ivermectin-induced fixed drug eruption in an elderly Cameroonian: a case report. J Med Case Rep. 2018;12(1):254.

Zaouak A, Ben Salem F, Ben Jannet S, Hammami H, Fenniche S. Bullous fixed drug eruption: A potential diagnostic pitfall: a study of 18 cases. Therapies. 2019;74(5):527–30.

Ben Fadhel N, Chaabane A, Ammar H, Ben Romdhane H, Soua Y, Chadli Z, et al. Clinical features, culprit drugs, and allergology workup in 41 cases of fixed drug eruption. Contact Dermatitis. 2019;81(5):336–40.

Shirvani MA, Motahari-Tabari N, Alipour A. The effect of mefenamic acid and ginger on pain relief in primary dysmenorrhea: a randomized clinical trial. Arch Gynecol Obstet. 2015;291(6):1277–81.

Harimurti S, Ulandari S, Widada H, Damarwati VL. Identifikasi Parasetamol dan Asam Mefenamat pada Jamu Pegel Linu dan Asam Urat yang Beredar di Daerah Istimewa Yogyakarta. JPSCR J Pharm Sci Clin Res. 2020;5(2):179.

Zhang J, Lei Z, Xu C, Zhao J, Kang X. Current Perspectives on Severe Drug Eruption. Clin Rev Allergy Immunol. 2021;61(3):282–98.

Crisafulli G, Franceschini F, Caimmi S, Bottau P, Liotti L, Saretta F, et al. Mild cutaneous reactions to drugs. Acta Bio Medica Atenei Parm. 2019;90(3-S):36–43.

Al-Mendalawi M. Prevalence of metabolic syndrome in patients with lichen planus: A cross-sectional study from a tertiary care center. Indian Dermatol Online J. 2019;10(3):340.

Cheraghlou S, Levy LL. Fixed drug eruptions, bullous drug eruptions, and lichenoid drug eruptions. Clin Dermatol. 2020;38(6):679–92.

Downloads

Published

2023-07-02

How to Cite

1.
Utami AP, Moelyono LA, Anadya R, Kusumamardhika R, Erdina. Bullous fixed-drug eruption with intraoral lesions due to mefenamic acid: A case report. J Pak Assoc Dermatol [Internet]. 2023Jul.2 [cited 2026Apr.18];33(2):775-9. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/2159

Issue

Vol. 33 No. 2 (2023): April-June

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.